Paper19200044
Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis.
Baiocco P and 3 others. Protein Pept Lett, 2009. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis. Papers, record 19200044. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19200044
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leishmania infantum | Major topic |
| NADH, NADPH Oxidoreductases | Major topic |
| Animals | |
| Cloning, Molecular | |
| Crystallography, X-Ray | |
| Electrophoresis, Polyacrylamide Gel | |
| Escherichia coli | |
| Recombinant Proteins | |
| Spectrophotometry, Ultraviolet |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42758390 | Antileishmanial activity of gold(I) compounds containing triphenylphosphine ligands against Leishmania amazonensis: impacts on mitochondrial bioenergetics and trypanothione reductase activity. | Biometals | 2026 | https://conductscience.org/library/papers/42758390 | PubMed |
| 41701359 | Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis. | J Mol Model | 2026 | https://conductscience.org/library/papers/41701359 | PubMed |
| 39088331 | Deciphering Host-Parasite Interplay in Leishmania Infection through a One Health View of Proteomics Studies on Drug Resistance. | ACS Infect Dis | 2024 | https://conductscience.org/library/papers/39088331 | PubMed |
| 38003236 | In Silico Exploration of the Trypanothione Reductase (TryR) of L. mexicana. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003236 | PubMed |
| 36615531 | Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site. | Molecules | 2023 | https://conductscience.org/library/papers/36615531 | PubMed |
| 34181199 | Druggable hot spots in trypanothione reductase: novel insights and opportunities for drug discovery revealed by DRUGpy. | J Comput Aided Mol Des | 2021 | https://conductscience.org/library/papers/34181199 | PubMed |
| 33945281 | Efficient Dimerization Disruption of Leishmania infantum Trypanothione Reductase by Triazole-phenyl-thiazoles. | J Med Chem | 2021 | https://conductscience.org/library/papers/33945281 | PubMed |
| 33842389 | Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania infantum, Causing Alterations in Redox Balance and Leading to Parasite Death. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/33842389 | PubMed |
| 32437349 | Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme. | PLoS Negl Trop Dis | 2020 | https://conductscience.org/library/papers/32437349 | PubMed |
| 31131262 | Immunomodulation From Moderate Exercise Promotes Control of Experimental Cutaneous Leishmaniasis. | Front Cell Infect Microbiol | 2019 | https://conductscience.org/library/papers/31131262 | PubMed |
| 30475811 | Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening. | PLoS Negl Trop Dis | 2018 | https://conductscience.org/library/papers/30475811 | PubMed |
| 29077741 | RNA-seq transcriptional profiling of Leishmania amazonensis reveals an arginase-dependent gene expression regulation. | PLoS Negl Trop Dis | 2017 | https://conductscience.org/library/papers/29077741 | PubMed |
| 28098499 | Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives. | J Enzyme Inhib Med Chem | 2017 | https://conductscience.org/library/papers/28098499 | PubMed |
| 21833767 | A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. | Amino Acids | 2012 | https://conductscience.org/library/papers/21833767 | PubMed |
| 21717278 | Evaluation of plumbagin and its derivative as potential modulators of redox thiol metabolism of Leishmania parasite. | Parasitol Res | 2012 | https://conductscience.org/library/papers/21717278 | PubMed |
| 21359528 | Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis. | Mol Cell Biochem | 2011 | https://conductscience.org/library/papers/21359528 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19200044
GET https://conductscience.org/api/papers/v1/19200044/authors